Clinical trial · Interventional
Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain
Comparison Between Ropivacaine/Dexamethasone and 10% Lignocaine Injection in Distal Glossopharyngeal Nerve Block for Intractable Cancer Pain- A Randomized Trial
NCT04085120CI-TRIAL-00040513unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will compare the efficacy and safety of Ropivacaine/dexamethasone vs 10% lignocaine injection in distal glossopharyngeal nerve block for intractable cancer pain
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Oropharynx | Malignant Oropharyngeal Neoplasm | ALIAS | 0.90 |
| Cancer Pain | — | UNRESOLVED | — |
| Pain, Intractable | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection | Procedure | — | UNRESOLVED |
| 10% lignocaine injection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Ropivacaine/dexamethasone group
- description
- 3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
- interventionNames
- Procedure: 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
- type
- EXPERIMENTAL
- label
- 10% lignocaine injection group
- description
- 4 ml of 10% lignocaine
- interventionNames
- Procedure: 10% lignocaine injection
Primary outcomes (1)
- measure
- Pain reduction on the basis of the Numeric rating scale (NRS).
- timeFrame
- 4 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with proven carcinoma of the oropharynx and supraglottic larynx with estimated survival of 3 months or more. * Pain lasting for at least 2 weeks with an average intensity of 5 or more on an 11-point numeric rating scale (NRS) refractory to a combination strong opioids and NSAIDS Exclusion Criteria: 1. Local infection or skin ulceration at the puncture site 2. Local anaesthetic allergy 3. Psychiatric illness that affected cooperation.
References
Publications (0)
Data not yet available
No reference posted for this study.